December 3, 2019

Pat Cotroneo
Senior Vice President and Chief Financial Officer
FIBROGEN INC
409 Illinois Street
San Francisco, CA 94158

       Re: FIBROGEN INC.
           Form 10-K for the Year Ended December 31, 2018
           Filed February 27, 2019
           File No. 001-36740

Dear Mr. Cotroneo:

      We have reviewed your filing and have the following comment. In our
comment, we
may ask you to provide us with information so we may better understand your
disclosure.

       Please respond to the comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to the comment, we may have additional
comments.

Form 10-K for the Year Ended December 31, 2018

ITEM 1. BUSINESS
PAMREVLUMAB FOR THE TREATMENT OF FIBROSIS AND CANCER
Clinical Development of Pamrevlumab , page 28

1.    Please address the following regarding your disclosure of certain serious
adverse events
      (SAEs) experienced by patients in the clinical development of
Pamrevlumab:
        You disclose on page 31 that there have been 45 SAEs in 31 patients,
four of which
          were considered possibly related by the principal investigator to
study treatment.
        Further, on page 34, you disclose that there were 99 TSAEs; six of
which were
          assessed as possibly related by the principal investigator, and 93 as
not related to
          study treatment.

      Please provide us proposed disclosure to be provided in future filings
identifying each
      treatment related SAE "possibly" related to Pamrevlumab.
 Pat Cotroneo
FIBROGEN INC
December 3, 2019
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       You may contact Sasha Parikh at 202-551-3627 or Rolf Sundwall at
202-551-3105 if you
have any questions.



FirstName LastNamePat Cotroneo                            Sincerely,
Comapany NameFIBROGEN INC
                                                          Division of
Corporation Finance
December 3, 2019 Page 2                                   Office of Life
Sciences
FirstName LastName